Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality.

Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Fry AM, Villanueva J, Gubareva LV.

J Infect Dis. 2014 Aug 1;210(3):435-40. doi: 10.1093/infdis/jiu105. Epub 2014 Feb 25.


Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.

Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Davis CT, Villanueva JM, Fry AM, Gubareva LV.

J Virol. 2015 May;89(10):5419-26. doi: 10.1128/JVI.03513-14. Epub 2015 Mar 4.


Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

Marjuki H, Mishin VP, Chesnokov AP, Jones J, De La Cruz JA, Sleeman K, Tamura D, Nguyen HT, Wu HS, Chang FY, Liu MT, Fry AM, Cox NJ, Villanueva JM, Davis CT, Gubareva LV.

J Infect Dis. 2015 Jan 15;211(2):249-57. doi: 10.1093/infdis/jiu447. Epub 2014 Aug 14.


R292K substitution and drug susceptibility of influenza A(H7N9) viruses.

Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva LV.

Emerg Infect Dis. 2013;19(9):1521-4. doi: 10.3201/eid1909.130724.


Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.

Itoh Y, Shichinohe S, Nakayama M, Igarashi M, Ishii A, Ishigaki H, Ishida H, Kitagawa N, Sasamura T, Shiohara M, Doi M, Tsuchiya H, Nakamura S, Okamatsu M, Sakoda Y, Kida H, Ogasawara K.

Antimicrob Agents Chemother. 2015 Aug;59(8):4962-73. doi: 10.1128/AAC.00793-15. Epub 2015 Jun 8.


Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.

Triana-Baltzer GB, Gubareva LV, Nicholls JM, Pearce MB, Mishin VP, Belser JA, Chen LM, Chan RW, Chan MC, Hedlund M, Larson JL, Moss RB, Katz JM, Tumpey TM, Fang F.

PLoS One. 2009 Nov 6;4(11):e7788. doi: 10.1371/journal.pone.0007788.


Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.

Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solórzano A, García-Sastre A, Palese P, Bouvier NM.

Nat Commun. 2013;4:2854. doi: 10.1038/ncomms3854.


Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment.

Liu Q, Ma J, Strayer DR, Mitchell WM, Carter WA, Ma W, Richt JA.

Expert Rev Anti Infect Ther. 2014 Feb;12(2):165-9. doi: 10.1586/14787210.2014.870885. Epub 2013 Dec 18.


Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.

Farooqui A, Huang L, Wu S, Cai Y, Su M, Lin P, Chen W, Fang X, Zhang L, Liu Y, Zeng T, Paquette SG, Khan A, Kelvin AA, Kelvin DJ.

Antimicrob Agents Chemother. 2015 Dec;59(12):7255-64. doi: 10.1128/AAC.01885-15. Epub 2015 Sep 14.


The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome.

Baranovich T, Burnham AJ, Marathe BM, Armstrong J, Guan Y, Shu Y, Peiris JM, Webby RJ, Webster RG, Govorkova EA.

J Infect Dis. 2014 May 1;209(9):1343-53. doi: 10.1093/infdis/jit554. Epub 2013 Oct 16.


The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets.

Yen HL, Zhou J, Choy KT, Sia SF, Teng O, Ng IH, Fang VJ, Hu Y, Wang W, Cowling BJ, Nicholls JM, Guan Y, Peiris JS.

J Infect Dis. 2014 Dec 15;210(12):1900-8. doi: 10.1093/infdis/jiu353. Epub 2014 Jun 20.


Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.

Triana-Baltzer GB, Gubareva LV, Klimov AI, Wurtman DF, Moss RB, Hedlund M, Larson JL, Belshe RB, Fang F.

PLoS One. 2009 Nov 6;4(11):e7838. doi: 10.1371/journal.pone.0007838.


Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.

Triana-Baltzer GB, Sanders RL, Hedlund M, Jensen KA, Aschenbrenner LM, Larson JL, Fang F.

J Antimicrob Chemother. 2011 Jan;66(1):15-28. doi: 10.1093/jac/dkq387. Epub 2010 Nov 21.


Combinations of oseltamivir and fibrates prolong the mean survival time of mice infected with the lethal H7N9 influenza virus.

Xu L, Bao L, Li F, Gu S, Lv Q, Yuan J, Xu Y, Zhu H, Deng W, Li Y, Yao Y, Yu P, Gao Z, Qin C.

J Gen Virol. 2015 Jan;96(Pt 1):46-51. doi: 10.1099/vir.0.069799-0. Epub 2014 Oct 1.


DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.

Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, Hawley S, Kim DH, Malakhov MP, Yu M, Fang F, Katz JM.

J Infect Dis. 2007 Nov 15;196(10):1493-9. Epub 2007 Oct 31.


DAS181 and H5N1 virus infection.

Zhang H.

J Infect Dis. 2009 Apr 15;199(8):1250, author reply 1250-1. doi: 10.1086/597479. No abstract available.


Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection.

Hedlund M, Aschenbrenner LM, Jensen K, Larson JL, Fang F.

J Infect Dis. 2010 Apr 1;201(7):1007-15. doi: 10.1086/651170.


The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice.

Zheng J, Wu WL, Liu Y, Xiang Z, Liu M, Chan KH, Lau SY, Lam KT, To KK, Chan JF, Li L, Chen H, Lau YL, Yuen KY, Tu W.

PLoS One. 2015 Aug 18;10(8):e0135999. doi: 10.1371/journal.pone.0135999. eCollection 2015.


Virological, serological, and antiviral studies in an imported human case of avian influenza A(H7N9) virus in Taiwan.

Lin PH, Chao TL, Kuo SW, Wang JT, Hung CC, Lin HC, Yang ZY, Ho SY, Chang CK, Huang MS, Chen HH, Chen YC, Lai HS, Chang SY, Chang SC, Yang PC.

Clin Infect Dis. 2014 Jan;58(2):242-6. doi: 10.1093/cid/cit638. Epub 2013 Sep 27.


Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.

Takano R, Kiso M, Igarashi M, Le QM, Sekijima M, Ito K, Takada A, Kawaoka Y.

J Infect Dis. 2013 Jan 1;207(1):89-97. doi: 10.1093/infdis/jis633. Epub 2012 Oct 10.

Supplemental Content

Support Center